Vascular endotheliAL growth factor and vascular endotheliAL growth factor receptor 2 in the blood serum, tumor and renal parenchyma of patients with renal cell carcinoma


Cite item

Full Text

Abstract

Serum, tumor and renal parenchyma levels of VEGF and VEGFR2 were compared in patients with renal carcinoma (RC) with reference to basic clinicomorphological characteristics of the disease. VEGF and VEGFR2 were estimated in 37 RC patients and 57 healthy controls (serum levels only). VEGF and VEGFR2 were detected in all the samples. Their concentrations in the serum were the same in the patients and controls. The tumor tissue contained more VEGF than renal parenchyma. In unfavorable clinicomorphological features the tumor contained higher content of VEGF, higher VEGF/VEGFR2, lower VEGFR2. Thus, angiogenic factors studied closely correlate with clinicomorphological characteristics of renal carcinoma: primary tumor size, stage of the disease, tumor differentiation, tumor pseudocapsule invasion.

References

  1. Трапезникова М. Ф. Опухоли почек. М.; "Медицина", 1978.
  2. Jacobsen J., Grankvist K., Rasmuson T., Ljungberg B. Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma. Br. J. Urol. Int. 2006; 97 (5): 1102-1108.
  3. Аксель Е. М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. Онкоурология 2005; 1: 6-9.
  4. Ficarra V., Martignoni G., Lohse C. et al. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer - specific survival using a European series of conventional renal cell carcinoma. J. Urol (Baltimore) 2006; 175 (4): 1235-1239.
  5. Носов А. К. Клинические проявления, диагностика и стадирование рака паренхимы почки. Практ. онкол. - 2005; 6 (3): 148-155.
  6. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 1972; 175 (3): 409-416.
  7. Кушлинский Н. Е., Герштейн Е. С. Биологические маркеры опухолей в клинике - достижения, проблемы, перспективы. Молекул. мед. - 2008; 3: 48-55.
  8. Ferrara N., Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS. 1997; 79: 209-232.
  9. Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002; 20: 4368-4380.
  10. Ferrara N., Gerber H. P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003; 9: 669-676.
  11. Rini B. I., Small E. J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J. Clin. Oncol. 2005; 23: 1028-1043.
  12. Paradis V., Lagha N. B., Zeimoura L. et al. Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch. 2000; 436: 351-356.
  13. Djordjevic G., Mozetic V., Mozetic D. V. et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol. Res. Pract. 2007; 203 (2): 99-106.
  14. Jacobsen J., Grandvist K., Rasmuson T. et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. Br. J. Urol. Int. 2004; 93: 297-302.
  15. Minardi D., Lucarini G., Mazzucchelli R. et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pT1a clear cell carcinoma in partial nephrectom specimens. J. Urol. (Baltimore) 2005; 174 (4): 1208-1212.
  16. Sato K., Tsuchiya N., Sasaki R. et al. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. Jpn J. Cancer Res. 1999; 90 (8): 874-879.
  17. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J. Urol. (Baltimore) 2000; 163 (1): 343-347.
  18. Schips L., Dalpiaz O., Lipsky K. et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur. Urol. 2007; 51 (1): 168-173.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies